impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Response to methotrexate predicts long-term mortality of patients with rheumatoid arthritis independent of the degree of response: results of a re-evaluation 30 years after baseline

1, 2, 3, 4, 5, 6, 7

 

  1. University of Münster, Germany.
  2. Department of Rheumatology, Evangelisches Fachkrankenhaus, Ratingen, Germany.
  3. Rheumazentrum Ruhrgebiet, Herne, Germany.
  4. Department of Medical Informatics, Biometry and Epidemiology, Ruhr-University, Bochum, Germany.
  5. Department of Rheumatology, Evangelisches Fachkrankenhaus, Ratingen, Germany.
  6. Department of Rheumatology, Evangelisches Fachkrankenhaus, Ratingen, Germany.
  7. Department of Medical Informatics, Biometry and Epidemiology, Ruhr-University, Bochum, Germany. gundi.krause@t-online.de

CER9681
2017 Vol.35, N°3
PI 0384, PF 0389
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 27974101 [PubMed]

Received: 25/06/2016
Accepted : 29/09/2016
In Press: 13/12/2016
Published: 07/06/2017

Abstract

OBJECTIVES:
To assess if there is a correlation between the degree of response to treatment with methotrexate (MTX) and long-term mortality in a cohort of patients with rheumatoid arthritis (RA) established in Germany in the early eighties.
METHODS:
RA patients who had started MTX treatment between 1980 and 1987 were included. One year after baseline, the treatment response was evaluated. Responders were defined as patients with at least 20% decline in the swollen joint count (out of 32 joints) and the ESR with a prednisone dosage <5 mg/day. Thereafter, assessments were performed at 10, 18, and 30 years after baseline. Standardised mortality ratios (SMR) were calculated, Cox regression and logistic regression were performed.
RESULTS:
The cohort comprised 271 patients. In 2015, about 30 years after the initiation of MTX therapy, 185 patients (68%) were deceased, 52 (19%) lost to follow-up and 34 alive. The response after the first year of MTX treatment was the strongest predictor of survival with a hazard ratio of 0.44 (95% confidence interval [CI]: 0.30-0.65). However, even responders still had an SMR of 1.37 (95% CI 1.31–1.65), but this was much worse for non-responders who had an SMR of 4.22 (95% CI 3.13–5.56). Using Cox regression analysis no difference was detected between responders with more than 50% improvement (38% of all patients) and those with 20–50% improvement (28%).
CONCLUSIONS:
The predictive value of a response to one year of MTX therapy for long-term mortality of RA patients is independent of the degree of response.

Rheumatology Article